U.S. Markets closed

Auxilium receives notification of Xiaflex PDUFA extension

Auxilium Pharmaceuticals announced that the FDA has notified the company that it is extending the Prescription Drug User Fee Act, or PDUFA, goal date for the company's supplemental biologics license application for XIAFLEX for the treatment of Peyronie's disease from September 6 to December 6.